Info@ThinkPinkRocks.org

Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced dosing of patients in the first-in-human clinical trials with KPT-330.

Read the original post:
Karyopharm commences two KPT-330 phase 1 studies in cancers

Scroll to Top